title: Blinatumomab-induced donor T-cell activation for post-stem cell transplant-relapsed acute CD19-positive biphenotypic leukemia.
abstract: Post-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph(+)) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.
authors.affiliation: Research Assistant, Hematology Department of Medicine, University of Arizona, AZ, USA.
authors.forename: Mohammed
authors.initials: M
authors.lastname: Alcharakh
authors.affiliation: Department of Medicine, University of Arizona, AZ, USA.
authors.forename: Seongseok
authors.initials: S
authors.lastname: Yun
authors.affiliation: Department of Pathology, University of Arizona, AZ, USA.
authors.forename: Yimin
authors.initials: Y
authors.lastname: Dong
authors.affiliation: Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, MN, USA.
authors.forename: Nicole D
authors.initials: ND
authors.lastname: Vincelette
authors.affiliation: Research Assistant, Hematology Department of Medicine, University of Arizona, AZ, USA.
authors.forename: Madiha
authors.initials: M
authors.lastname: Daud
authors.affiliation: Research Assistant, Hematology Department of Medicine, University of Arizona, AZ, USA.
authors.forename: Saima
authors.initials: S
authors.lastname: Manzoor
authors.affiliation: Research Assistant, Hematology Department of Medicine, University of Arizona, AZ, USA.
authors.forename: Irbaz Bin
authors.initials: IB
authors.lastname: Riaz
authors.affiliation: Department of Medicine, University of Arizona, AZ, USA.|Division of Hematology, Oncology, Blood & Marrow Transplantation, University of Arizona, Tucson, AZ 86721, USA.
authors.forename: Faiz
authors.initials: F
authors.lastname: Anwer
mesh_terms: D018033:Antibodies, Bispecific / Q000627:therapeutic use*; D018941:Antigens, CD19 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology*; D017252:CD3 Complex / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000276:immunology / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D033581:Stem Cell Transplantation; D013601:T-Lymphocytes / Q000276:immunology*; D014019:Tissue Donors
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D000970:Antineoplastic Agents; D017252:CD3 Complex; C510808:blinatumomab
keywords: Blinatumomab; CD19; biphenotypic acute leukemia